Registration for a live webinar on 'Innate immunity, inflammation and cancer' is now open.
See webinar details
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Epidemiology and risk factors
-
30 min
1. Epidemiology of COPD- Dr. David Mannino
-
36 min
2. COPD in never smokers- Dr. Sundeep Salvi
-
43 min
3. Genetics of chronic obstructive pulmonary disease (COPD)- Prof. Martin Tobin
- Phenotypes of COPD
-
44 min
4. COPD and asthma: similarities and differences- Prof. Peter Barnes
- Pathophysiology and mechanisms of COPD
-
43 min
5. The pathology of chronic obstructive pulmonary disease- Prof. James Hogg
-
63 min
6. The continuum of COPD: a physiological perspective- Prof. Denis O'Donnell
-
47 min
7. Inflammatory and immune mechanisms in COPD- Prof. Peter Barnes
-
44 min
8. Mechanisms of COPD exacerbations and relation to exacerbation therapy- Prof. Wisia Wedzicha
-
39 min
9. Protease-antiprotease balance- Prof. Robert Stockley
- Therapy and management
-
42 min
10. Updates in chronic obstructive pulmonary disease (COPD)- Dr. Omar S. Usmani
-
45 min
11. Long-acting bronchodilators in COPD- Prof. Bart Celli
-
54 min
12. Treatment of COPD exacerbations- Prof. Antonio Anzueto
-
25 min
13. Pulmonary rehabilitation: history, promise and problems- Prof. Richard Casaburi
-
29 min
14. Lung volume reduction: advances in COPD- Dr. Nick Hopkinson
-
35 min
15. New pharmacological therapies for COPD- Prof. Peter Barnes
-
32 min
16. The Salford lung study in COPD- Dr. Dave Leather
- COPD case studies
-
11 min
17. COPD treatment case I: COPD with “bronchitis attacks”- Dr. Janwillem Kocks
-
13 min
18. COPD treatment case II: COPD with asthma as child- Dr. Janwillem Kocks
-
12 min
19. COPD treatment case III: COPD with pre-diabetes- Dr. Janwillem Kocks
-
48 min
20. Tailoring care for advanced COPD- Prof. Wissam Chatila
- Archived Lectures *These may not cover the latest advances in the field
-
59 min
21. Alpha-1 antitrypsin deficiency: state of the art- Dr. Jamie Stoller
-
34 min
22. Oxidative stress in COPD- Prof. William MacNee
-
24 min
23. Managing co-morbidity in COPD- Dr. John Hurst
-
40 min
24. Clinical phenotypes of COPD- Prof. Jørgen Vestbo
-
27 min
25. Pulmonary rehabilitation: focusing on rehabilitative exercise- Prof. Richard Casaburi
-
36 min
26. Genetics of COPD- Prof. Ian Hall
Printable Handouts
Navigable Slide Index
- Introduction
- Outline
- COPD definition - GOLD 2010
- Changes in COPD definition
- Lung function categories
- FEV1/FVC ratio decreases with increasing age
- Lung function in 1000 "COPD" patients
- COPD severity - U.S.
- COPD severity - England
- COPD severity - BOLD
- COPD progression (1)
- COPD progression (2)
- Natural history of chronic airflow obstruction
- What is progression of COPD?
- Diagnosed lung disease & function impairment
- Disease prevalence
- Prevalence of COPD
- Prevalence of COPD 2006 update (1)
- Prevalence of COPD 2006 update (2)
- The PLATINO and BOLD studies
- BOLD sites
- Prevalence of GOLD 2 COPD
- COPD prevalence, by sex, in U.S., 1980-2000
- Decreasing prevalence in Spain?
- No increase in Finland
- Risk of COPD among smokers
- Risk of COPD by age (10 year increase)
- GOLD 2 COPD risk factors: never smoking men
- GOLD 2 COPD risk factors: never smoking women
- Biomass fuel and COPD in China
- Early life exposures (1)
- Early life exposures (2)
- Hospitalizations
- A paradigm of exacerbations (1)
- A paradigm of exacerbations (2)
- COPD exacerbation rate
- COPD hospitalization rate
- End-of-life - disease C (1)
- COPD hospitalizations - U.S. (1980-2000)
- COPD hospitalizations - U.S. (1990-2005)
- Long-term follow-up of U.S. cohorts (1)
- Risk of death following COPD hospitalization
- Long-term follow-up of US cohorts (2)
- Risk of hospitalization
- Mortality
- End-of-life - disease C (2)
- Survival by lung function impairment
- What do COPD patients die from?
- COPD - consequences and comorbidities
- Risk of death within 5 years from baseline
- Mortality following exacerbation
- COPD deaths by sex, race; U.S., 1980 - 2000
- COPD deaths by region; U.S., 1980 - 2000
- Improving survival after COPD hospitalization
- Improving COPD mortality in U.S.
- Conclusions (1)
- Conclusions (2)
- COPD is a preventable and treatable disease
Topics Covered
- GOLD guidelines for COPD
- Lung function categories
- BOLD initiative
- Exacerbation rates for COPD patients
- Hospitalization rates for COPD patients
- Reasons for mortality in COPD patients
- Update interview: An expanded definition of COPD from COPDGene
- Update interview: Key lung function trajectories in the development of COPD
- Update interview: Overlap syndromes with COPD, including asthma, pulmonary fibrosis, obstructive sleep apnea
- Update interview: Combination therapies in the treatment of COPD
- Update interview: Improvement in COPD metrics (hospitalization and mortality)
Links
Series:
Categories:
Therapeutic Areas:
Talk Citation
Mannino, D. (2021, June 27). Epidemiology of COPD [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2024, from https://hstalks.com/bs/2357/.Export Citation (RIS)
Publication History
Financial Disclosures
- Dr. David Mannino, Consultant: GlaxoSmithKline, Merck, Novartis, Nycomed, Forest; Speaker’s Bureau: Merck, GlaxoSmithKline; Grant/Research Support (Principal Investigator): GlaxoSmithKline, Forest, Boerhinger-Ingelheim.
Update Available
The speaker addresses developments since the publication of the original talk. We recommend listening to the associated update as well as the lecture.
- Full lecture Duration: 30:21 min
- Update interview Duration: 12:43 min
Epidemiology of COPD
A selection of talks on Clinical Practice
Transcript
Please wait while the transcript is being prepared...